Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print   

Friday 10 September, 2021

BioPharma Credit PLC

Notice of GM

RNS Number : 3309L
BioPharma Credit PLC
10 September 2021
 

LEI: 213800AV55PYXAS7SY24

10 September 2021

BIOPHARMA CREDIT PLC

(THE "COMPANY")

INTENTION TO APPLY FOR ADMISSION OF ORDINARY SHARES TO LISTING ON THE PREMIUM SEGMENT OF THE MAIN MARKET, PUBLICATION OF CIRCULAR AND NOTICE OF GENERAL MEETING

BioPharma Credit plc (the "Company" or "BioPharma Credit") announces its intention to apply for admission of its ordinary shares (the "Ordinary Shares") to listing on the Premium Segment of the Official List and the transfer of the admission to trading of the Ordinary Shares from the Specialist Fund Segment to the Premium Segment of the London Stock Exchange plc's Main Market (the "Admission"), subject to the passing of certain resolutions to be proposed at a general meeting of the Company to be held at the offices of Herbert Smith Freehills LLP, Exchange House, Primrose Street, London EC2A 2EG at 3.30 p.m. (London time) on 30 September 2021 (the "General Meeting").

It is also proposed that the Company will submit an application to cancel the admission of the Ordinary Shares on the Official List of The International Stock Exchange Authority Limited ("TISEA") on or shortly after, and conditional upon, Admission.

 

A notice of the General Meeting is contained in the shareholder circular (the "Circular") published today on the Company's website at http://bpcruk.com . In addition, a copy of the Circular has been submitted to the National Storage Mechanism and will shortly be available for viewing online at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism . Shareholders are advised to read the whole of the Circular with care.

As described more fully in the Circular, in order to be eligible for Admission and to comply with the Listing Rules, the Company must, among other things, amend its articles of association (including to make certain revisions to its current shareholder voting structure) and adopt a written investment policy.

The Company believes that the Premium Segment of the Main Market is the most appropriate platform for the continued growth of the Company, as the transition is expected to increase the Company's profile, broaden its shareholder register and facilitate the Company's eligibility for inclusion in the FTSE UK Index Series.

Continuation Resolution

 

Under the Company's existing articles of association, an ordinary resolution that the Company continues its business at as a closed-ended investment trust (a "Continuation Resolution") is scheduled to be held at the Company's annual general meeting in 2022. However, the Directors believe that it is beneficial to the Company for the Continuation Resolution to be held earlier, for the reasons set out more fully in the Circular.

 

As more fully described in the Circular, the Company is therefore proposing to amend its articles of association to permit the Continuation Resolution to be put to shareholders at the General Meeting. Subject to the approval of the shareholders to such amendments, the Continuation Resolution will be proposed at the General Meeting as an ordinary resolution.


Working Capital

The Company is of the opinion that the working capital available to the Company is sufficient for its present requirements, that is for at least the next 12 months from the date of this announcement.

For Further Information

BioPharma Credit plc

Via Link Company Matters Limited

Company Secretary
+44 (0)1392 477 509

 

J.P. Morgan Cazenove   

William Simmonds / Harry Randall (Corporate Finance)

+44 (0)20 7742 4000

Buchanan

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

+44 (0)20 7466 5000

[email protected]

 

About BioPharma Credit plc:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

Visit the BioPharma Credit website at http://bpcruk.com for more information.

Capitalised terms used but not defined in this announcement will have the same meaning as set out in the Circular unless the context otherwise requires.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOGSSIFMUEFSEDU

a d v e r t i s e m e n t